Project Grant R01AI184768
Award Date
5/5/25
Completion Date
4/30/30
Dollars Obligated
$798K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $896,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Texas Medical Branch at Galveston (UTMB). The grant, titled "Modulation of Viral Genome Packaging in Rift Valley Fever Virus", will fund research to expand the understanding of viral RNA packaging mechanisms in Rift Valley Fever virus, a dangerous mosquito-borne virus that could pose serious...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the immunological mechanisms of self-replicating RNA (RepRNA) vaccines delivered using muscle-localizing cationic nanocarriers (LION). The primary objectives are to characterize the role of skeletal muscle dendritic cells, understand how type I interferon signaling inhibits transgene...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $668,569 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Schepens Eye Research Institute, Inc. in Boston, MA. The grant will fund research to characterize and optimize a novel genetic vaccine platform called PARVAX, with the goal of increasing its clinical acceptance and application for pandemic preparedness. Key objectives include investigating the mechanism behind the...
The University of Texas Medical Branch at Galveston (UTMB) received a Project Grant award of $636,101 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will fund research to elucidate the mechanism of viral RNA packaging and co-packaging in Rift Valley Fever Virus (RVFV), a bunyavirus that poses significant public health and agricultural risks. The research aims to gain insights into the...
This $299,969 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate a mosquito salivary protein, AGBR1, as a vaccine candidate against Chikungunya virus. The goal is to confirm that vaccination with AGBR1 can protect against Chikungunya infection in mouse models, including both acute lethal infection and chronic disease manifestations like joint pain and...
The University of California, Irvine received a $33,116,067 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct basic and translational research for developing prototype vaccines against emerging viruses. The key products and services to be delivered include: Characterization and comparison of two universal, programmable, rapid response vaccine platforms: an...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel T cell-based vaccine to prevent Dengue and Zika virus infections. The $781,718 award will fund research to create a vaccine that targets the non-structural protein 3 (NS3) of Zika and Dengue viruses, using a gene rearrangement and ubiquitination strategy to enhance T cell responses without causing...
This $883,119 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The key goals are to investigate viral and cellular factors that hinder effective HBV antigen expression, and to improve the vaccine antigens to elicit potent antibody and T cell responses that can help cure HBV...
This federal Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), totals $38,056,004 and is focused on developing strategies effective against pathogenic picornaviruses and bunyaviruses. The award supports five research projects that aim to advance vaccine and antibody-based countermeasures for viruses such as enteroviruses, hantaviruses, and arenaviruses. Key products and...
This $3,156,840 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a universal vaccine against leptospirosis. The key objectives are to evaluate a multi-recombinant protein vaccine candidate for its ability to elicit cross-protective immune responses against diverse Leptospira species, and to identify conserved B-cell epitopes that could form the basis of a...